Telemedicine is effective to diagnose and treat various dermatologic conditions in the pediatric population.
Telemedicine is effective for the diagnosis and treatment of multiple dermatological conditions in the pediatric community, with significant patient and provider satisfaction, according to the Journal of the American Academy of Dermatology International.
Teledermatology’s implementation into dermatologic care might increase care access locally and globally, but hurdles to commitment persist.
This review was conducted because the use of teledermatology instantly intensified upon the onset of COVID-19 and study authors wanted to review recent studies concerning the efficacy, perception, and utilization of telemedicine in pediatrics.
The study authors aim was to analyze the present state of pediatric dermatology through a systematic literature review.
Pediatric access to dermatologists is limited. Since the onset of COVID-19, teledermatology has been proposed as a way to improve dermatologic services for pediatric patients, though the present state of virtual medicine is in flux.
A literature search was conducted, and a total of 44 articles published between 2008 and 2022 were used.
Results revealed that diagnostic concordance between pediatric teledermatologist and in-person dermatologist varied from 70% to 89%. Teledermatology patient satisfaction was between 70% to 98%, with provider satisfaction around 95%. Teledermatology integration can decreased missed appointments and wait times for pediatric patients. Still, significant technological challenges persist, especially in underserved communities. Around the world, teledermatology might increase care access, even though narrow literature exists about its use in the pediatric community.
In the review, it was found that some conditions were accurately diagnoses by nondermatologists, but various others needed specific dermatological knowledge that may account for the varying range of concordance (39% to 82%) in the studies reviewed.
Generally, the literature suggests that diagnostic and management concordance is fairly high and validates the effectiveness of pediatric teledermatology for various dermatologic diseases.
Regardless of multiple studies showing the treatment of skin conditions through telemedicine, agreement on the optimal modality for individual dermatologic treatment in the pediatric community is still ambiguous.
There was a lower no-show rate of in-person visits after e-consult referrals compared with appointments created through a traditional referral system (39% vs 71%) in pediatric patients.
More studies are needed to understand the varied impact of different communication methods on the general efficacy and need for in-person follow-up after telemedicine, and which conditions are more likely to need an in-person follow up after a virtual visit.
Study design variability might also support the discrepancy in reported conditions before and after the pandemic.
Multiple publications have indicated high satisfaction rates with telemedicine use between pediatric patients, parents, and dermatologists, which may be due to increasing acceptance for technology’s role in clinical care.
Generally, pediatric dermatologists reported positive feedback about the use of telemedicine. Simultaneously, physicians are still worried about the quality of care given via telemedicine, where, according to one survey, 65% of pediatric dermatologists felt that teledermatology was not as effective as care in-person, and 46% thought that mistakes were more likely to take place. Just 8% said that treatment outcomes were the same as in-person care. Future studies should evaluate the role of physician assistants and nurse practitioners with teledermatology in the pediatric population.
The adoption and utilization of pediatric teledermatology isn’t well-characterized, and supplementary factors limit medical care access in these populations, like financial constraints, parental health, and inadequate transportation.
“Teledermatology imposes its own barriers on low-income communities, specifically, the need for a reliable and strong internet connection, computers or smart devices, digital literacy, the need for translator services, and the availability of a private location for the visit,” said the study authors.
However, there is strong evidence that teledermatology in the pediatric population can increase care access for underserved communities, with one multicenter study illustrating a 9% to 21% decrease in missed pediatric dermatology appointments when telemedicine was used in urban safety net clinics.
“Additionally, the integration of virtual visits was correlated with a significant reduction in wait times for appointments for this condition (17 days vs 28 days),” said the study authors, referring to a different study.
Some limitations of this study included the inability to incorporate literature that didn’t come up in certain search databases, and that it is possible that relevant articles were accidentally missed.
“Although studies have demonstrated successful use of pediatric teledermatology in underserved communities, the broader uptake and utilization of this method of care in vulnerable populations is unclear. Technological barriers and lack of clarity on reimbursement structure remain significant barriers to implementation and acceptance,” the researchers concluded.
Reference
Burshtein J. Buethe MG, Ghias MH, Stein AB, Glick S, Marmon S. Efficacy, perception, and utilization of pediatric teledermatology: a systematic review. JAAD Int. Published online March 29, 2023. doi: 10.1016/j.jdin.2023.03.005
Combining Surgical, Nonsurgical Approaches Holds Promise for Treating Facial Acne Scars
May 4th 2024According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.
Read More
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More